About Diabetes
Complications
Warning Signs
Screening Test
Donate Now
E-Lerts™
Index
Latest News
Diabetes Terms
Health & Fitness
Online Press Center
Exubera, The Inhaled
Insulin Passes FDA
posted March 18, 2005
The US Food and Drug Administration
has accepted a new drug application by Sanofi-Aventis and Pfizer of the United
States for Exubera, a dry powder form of insulin that is inhaled into the lungs
prior to eating.
The companies want to provide Exubera to adult patients with type 1 (the most
serious) and type 2 diabetes, a joint statement said.
Exubera is currently also under review by the European Medicines Evaluation
Agency.
The treatment has been tested on more than 3,400 patients, some for more than
seven years, the statement said. "It is estimated that nearly 180 million people
worldwide suffer from diabetes, and the number is expected to rise to 300
million people in the next 20 years," it added.
Diabetes and associated complications cost more than USD 100 million (EUR 75
million) per year in the US, the drug companies said.
Source: Diabetes In Control.com.
|
|
|
Home - About Diabetes - Complications - Warning Signs - Screening Test - Donate Now - Special Events - Latest News - Health & Fitness - Online Press Center - E-Lerts Index - Meet Mr. Diabetes® - Wake Up And Walk® Tour - About Us - Diabetes Terms - Site Search - Your Diabetes Profile - Privacy Policy - Legal Notices - How to Contact Us - Comments form - Suggestion Form - Our E-Mail Addresses - Our Address and Phone Numbers - Links - Contact Us To be sure and come back to keep up with all the
Latest News and important information for diabetics - and to remind
yourself to manage and control your diabetes, click the yellow link
below
to add a small icon of our Defeat Diabetes® "Torch"
logo to your desktop. All you need to do after that is
click on the "Torch" to open our website.
Remember, we're here for you!
Translate this page into Spanish using FreeTranslation.com. © Copyright 2001 - 2004, Defeat Diabetes Foundation, Inc., All Rights Reserved |
We
subscribe to the HONcode principles